Compare Amgen, Inc. (AMGN) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs M&T Bank Corporation — how do they compare? Amgen, Inc. trades at $410.99 (market cap $224.14B), while M&T Bank Corporation trades at $251.93 (market cap $36.42B). The key difference: Amgen, Inc. is far larger — about 6.2× M&T Bank Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | MTB | |
|---|---|---|
Market Cap | $224.14B | $36.42B |
Sector | Health | Financials |
52-Week High | $417.20 | $254.04 |
52-Week Low | $271.18 | $178.63 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
M&T Bank (MTB) trades at $251.13, up 0.27% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows consistent revenue growth, with 2025 revenue at $9.63B and net income margin of 29.59%, supported by a P/E of 13.35. Analyst consensus is a Hold with a $255.92 price target, while recent news highlights robust Q2 2026 results and dividend stability.
Outlook remains positive due to earnings momentum and loan growth, but risks include rising costs and macroeconomic pressures. The stock offers value with a reasonable valuation and dividend yield, though investor caution is warranted amid mixed analyst ratings and net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
